The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The value of ctDNA biomarkers in colorectal and non-small cell lung cancer
Erika Ruiz-Garcia, MD, Instituto Nacional de Cancerologia, Mexico City, Mexico, discusses the role of circulating tumor DNA (ctDNA) as a prognostic biomarker in cancer, highlighting its potential in colorectal cancer and non-small cell lung cancer. While ctDNA shows promise, more research is needed to establish its utility as a predictive biomarker, and limitations in its usage still persist due to cost, especially outside of the US and Europe. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ctDNA is a very important tool. It doesn’t have FDA approval yet, but we know that with the data that has been performed by several groups of researchers, that ctDNA , at least for colorectal cancer and non-small cell lung cancer, it’s a good prognostic biomarker. On the other hand, what about the predictive biomarker? Well, there is more information that is needed before we can apply it...
ctDNA is a very important tool. It doesn’t have FDA approval yet, but we know that with the data that has been performed by several groups of researchers, that ctDNA , at least for colorectal cancer and non-small cell lung cancer, it’s a good prognostic biomarker. On the other hand, what about the predictive biomarker? Well, there is more information that is needed before we can apply it. And this is very important because ctDNA tests outside of the U.S. and some parts of Europe are a very expensive test. So it is not so easy for patients to pay for this kind of test out of their pocket. So it’s so relevant that we as clinicians understand perfectly how the ctDNA test assays are, what the goals of those kinds of assays are, because there are different types of assays and they are so expensive that we need to use them wisely.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
